Amyloid-β peptides slightly affect lifespan or antimicrobial peptide gene expression in Drosophila melanogaster

Mikhail V. Shaposhnikov1,2, Nadezhda V. Zemskaya2, Lyubov А. Koval2, Natalya R. Minnikhanova2, Olga I. Kechko1, Vladimir A. Mitkevich1, Alexander A. Makarov1 and Alexey А. Moskalev1,2*

From 11th International Young Scientists School “Systems Biology and Bioinformatics” – SBB-2019
Novosibirsk, Russia. 24-28 June 2019

Abstract

Background: Beta-amyloid peptide (Aβ) is the key protein in the pathogenesis of Alzheimer’s disease, the most common age-related neurodegenerative disorder in humans. Aβ peptide induced pathological phenotypes in different model organisms include neurodegeneration and lifespan decrease. However, recent experimental evidence suggests that Aβ may utilize oligomerization and fibrillization to function as an antimicrobial peptide (AMP), and protect the host from infections. We used the power of Drosophila model to study mechanisms underlying a dual role for Aβ peptides.

Results: We investigated the effects of Drosophila treatment with three Aβ42 peptide isoforms, which differ in their ability to form oligomers and aggregates on the lifespan, locomotor activity and AMP genes expression. Aβ42 slightly decreased female’s median lifespan (by 4.5%), but the effect was not related to the toxicity of peptide isoform. The lifespan and relative levels of AMP gene expression in male flies as well as locomotor activity in both sexes were largely unaffected by Aβ42 peptide treatment. Regardless of the effects on lifespan, Aβ42 peptide treatment induced decrease in AMP genes expression in females, but the effects were not robust.

Conclusions: The results demonstrate that chronic treatment with Aβ42 peptides does not drastically affect fly aging or immunity.

Keywords: Lifespan, Aging, Drosophila melanogaster, Amyloid-β peptides, Antimicrobial peptides, Transcription factor FOXO, Peroxiredoxin 5

Background

Traditionally beta-amyloid peptide (Aβ) considered as the key protein in pathology of Alzheimer’s disease (AD), the most common inflammatory neurodegenerative disease in humans [1, 2]. The accumulation and deposition of insoluble, aggregated Aβ peptides in extracellular amyloid plaques in the brain is one of the pathological hallmarks of AD [3]. The soluble Aβ oligomers act as active neurotoxins, causing neuronal dysfunction, loss of synaptic connections, cell death, and subsequent detrimental events of AD [4, 5].

However, a growing body of evidence suggests that Aβ can also possesses physiological roles [6, 7]. Particularly Aβ may function as an antimicrobial peptide (AMP), a component of the innate immune system...
genes in aging flies [22, 23]. It was also noted that the significant increase in the level of expression of AMPs aging-associated changes in the transcriptome revealed a significantly shortened lifespan [21]. An earlier analysis of the and specifically with lifespan [23]. Underexpression of Relish in the level of AMPs expression in young flies correlates negatively [8, 9]. Aβ utilizes oligomerization and fibrillization to protect the host from a broad spectrum of infectious agents including protozoans, fungi, bacteria, mycobacteria, and enveloped viruses [7, 8].

The fly model allows using the power of D. melanogaster genetics to identify mechanisms underlying the effects of exogenous β-amyloid peptides [10, 11]. Although endogenous Aβ peptides are not produced normally in Drosophila [12], neurodegenerative phenotypes induced by the exogenous Aβ peptides in Drosophila suggest a conserved function [10, 11]. Overexpression of human Aβ42 peptides in the nervous system of the fly results in phenotypes associated with neuronal degeneration [10, 13], locomotor decline [14, 15] and a lifespan decrease [16]. No positive effects of exogenous Aβ peptides in Drosophila model was published to date. However, since the microbial quantity is a predictor of fly longevity [17], we assume that the benefits of exogenous Aβ may be possible because of its antimicrobial activity.

Previous studies have shown that constitutive ubiquitous overexpression of anti-microbial peptide gene Diptericin is sufficient to increase antioxidant enzyme activities and tolerance to hyperoxia [18]. Conditional (RU486-mediated) activation of ubiquitous or gut specific overexpression of single AMP genes Drosocin and CecropinA1 in adult flies leads to reduced immune challenge or intestinal stress response, improved intestinal integrity and lifespan [19]. We previously showed that the lifespan extending effect of pectins is associated with activation of expression of the NF-κB-dependent AMP genes Defensin, Drosomycin and Metchnikowin [20]. At the same time constitutive ubiquitous or fat body specific activation of expression of several different classes of Relish target AMPs (including Attacin A, Attacin C, Attacin D, Cecropin A1, Defensin, Diptericin, Drosocin, Drosomycin, and Metchnikowin) or overexpression of some individual AMP genes (including Attacin A, Cecropin A1, Defensin, and Metchnikowin, but not Drosocin and Drosomycin) induced cytotoxic effects and significantly shortened lifespan [21]. An earlier analysis of the aging-associated changes in the transcriptome revealed a significant increase in the level of expression of AMP genes in aging flies [22, 23]. It was also noted that the level of AMPs expression in young flies correlates negatively with lifespan [23]. Underexpression of Relish in the fat body beginning in the second half of lifespan prevented age-related overactivation of AMPs and extended longevity [21]. We also found that life-long pharmacological inhibition of NF-κB activity increases Drosophila lifespan [24]. Numerous studies demonstrated that stimulation of AMPs production by activation of upstream components of the innate immunity cell signaling pathways, such as peptidoglycan recognition protein (PGRP-LE) [25] or suppressing negative regulators, such as dnr1 [26], or pirk, trbd, and tg [27], lead to proinflammatory state, neurodegeneration, and shortened lifespan. Thus, AMPs as well as Aβ peptides can be either harmful or protective in different model systems and experimental conditions.

The aim of this work was to investigate the effects of exogenous amyloid-β peptides on Drosophila lifespan and locomotor activity. Since Aβ peptides has AMP activity and treatment with Aβ would be expected to influence infection rates, we analyzed the mRNA level of the antimicrobial peptide genes. In this study, we used 3 amyloid-β peptide isoforms, associated with human AD, including Aβ42 (non-modified Aβ, one of the main variants associated with familial forms of AD), isoD7-Aβ42 (Aβ42 peptide variant with isomerized Asp7, one of the most abundant age-related Aβ species within amyloid plaques) [28, 29], and pS8-Aβ42 (phosphorylated variant of Aβ42 with increased ability to form toxic aggregates as compared with Aβ42, involved in the pathogenesis of the most common sporadic form of AD) [30]. We revealed that Aβ42 and pS8-Aβ42, but not more toxic Aβ42 form isoD7-Aβ42, induced minor decline of female’s median lifespan while lifespan in male flies and locomotor activity in both sexes were not affected. The expression level of AMP genes (CecropinA1, Defensin, Drosocin, Drosomycin, and Metchnikowin) in males and females was slightly changed regardless of the effects on lifespan. The obtained results suggest that chronic treatment with Aβ42 weakly affects Drosophila aging and immunity.

Results
Lifespan and locomotor activity
The statistically significant effects of Aβ42, isoD7-Aβ42, and pS8-Aβ423 on male’s lifespan were not detected (p > 0.05, Fisher’s exact and log-rank tests) (Table 1, Fig. 1a). Using Cox proportional hazards analysis (Table 2) we found that in Aβ42 and isoD7-Aβ42 male variants there was an elevated hazard ratio (risk of death) of vial covariates (p < 0.01, likelihood ratio test), while effects of Aβ treatment remained insignificant (p > 0.05, likelihood ratio test). It was found that Aβ42 and pS8-Aβ42, but not isoD7-Aβ42 caused a statistically significant decrease in the median lifespan of females by 4.5% (p < 0.01, Fisher’s exact test) (Table 1, Fig. 1b). The hazard ratio of the females treated with Aβ42 peptide was slightly (1.201 times) increased (p < 0.05, likelihood ratio test) compared to those of the control flies (Table 2).

In addition to the lifespan, the spontaneous locomotor activity was used for Aβ toxicity analysis (Fig. 1c and d). Locomotor activity of Aβ treated males was unaffected (Fig. 1c). Despite locomotor activity of Aβ42 (by 36.8%) and pS8-Aβ42 (by 18.0%) treated females at the age of 6 weeks showed decrease compared with control untreated females (p < 0.01, Student’s t-test) (Fig. 1d) ANOVA
revealed that there is no a statistically significant difference between the control and Aβ treated animals ($p > 0.05$, Source of variation: Conditions) (Table 3). At the same time by using the ANOVA, we showed a significant difference in movement capacity between male and female flies of different ages in control and experimental variants ($p < 0.001$, Source of variation: Age) (Table 3).

Numerous studies have previously shown that overexpression of Aβ significantly shortened Drosophila lifespan and locomotion function [13, 14]. Our results demonstrate that treatment with Aβ peptides induces a minor reduction in female lifespan, but more toxic Aβ42 form has no effect on female lifespan. Locomotor activity of Aβ overexpressed flies may demonstrate a progressive decrease during ageing, which is caused by Aβ peptide accumulation [30]. However, we did not observe overt effect of Aβ peptides on locomotion.

**Gene expression**

We used the reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) to determine the effects of Aβ on the expression level of main AMP genes of *Drosophila*, namely: Cecropin A1 (CecA1), Defensin (Def), Drosocin (Dro), Drosomycin (Drs), and Metchnikowin (Mtk).

As compared with control variant, in males Aβ42 treatment induced 18-fold decrease of CecA1 expression level, isoD7-Aβ42-5.3-fold increase of Mtk expression level, and pS8-Aβ42 increased expression level of CecA1 (2-fold) and Dro (17.3-fold) (Fig. 1e). However, these changes did not affect lifespan and locomotor activity of males. We also found that treatment with Aβ peptides results in a 1.5- to 16.9-fold decrease in AMP genes expression relative to controls in females (Fig. 1f). The most significant negative effect on the level of AMP expression in females was induced by unmodified Aβ42 form.

Previous studies have shown the importance of oxidative stress in Aβ42 peptide toxicity in fly model [14]. We analyzed the expression level of redox-sensing enzyme gene Peroxiredoxin 5 (Prx5), a negative regulator of the *Drosophila* immune response which is involved in trade-off between the antioxidant and immune functions [31]. Treatment with phosphorylated Aβ42 isoform, pS8-Aβ42 caused 6-fold elevation in the level of the Prx5 in females, while other Aβ peptide did not affect the Prx5 gene expression in males and females (Fig. 1e and f). We then investigated the expression level of transcription factor dFOXO, a positive regulator of the *Drosophila* AMPs [32] and found 4–5 fold decrease in the dFOXO mRNA levels in females (Fig. 1f). In addition, FOXO is a downstream component of insulin/IGF signaling pathway, which modulation may be associated with Aβ toxicity [33].

Since all variants of female treatment with Aβ peptides lead to similar changes in the level of AMP genes expression, but the effects on lifespan were observed in the Aβ42 and pS8-Aβ42 treated variants only, it can be concluded that changes in the relative levels of AMP genes expression were not sufficient to influence lifespan.

It should also be noted that our results are consistent with the previously described differences between males and females including the longer lifespan of females, the significantly higher locomotor activity in males, and gene expression levels as well as sex differences in the effects of pharmacological interventions on these parameters [34–36].

**Discussion**

In this study the treatment with Aβ peptides causes a weak negative effect on the lifespan and slightly decreases the expression level of AMP genes of *Drosophila* females while locomotor activity is not affected. The activities of AMPs negative regulator Prx5 and positive regulator dFOXO were increased and decreased, respectively. Probably a decrease of the production of endogenous AMPs may be due to the antimicrobial properties of exogenous Aβ peptides as it can have bactericidal properties.

The antimicrobial properties of Aβ peptides are well documented and believed to be caused by the ability to entrap pathogens and disrupt cell membranes with the mechanisms of oligomerization and fibrillation [7, 8].

### Table 1 Influence of Aβ peptides on median and maximum lifespan

| Variant       | Sex | M (days) | dM (%) | FET (p) | 90% (days) | d90% (%) | WAT (p) | n  |
|---------------|-----|----------|--------|---------|------------|----------|---------|----|
| control       | male| 56       | 0.0    | 0.4706  | 66         | 0.0      | 0.464   | 275|
| Aβ42          | male| 56       | 0.0    | 0.3906  | 64         | −3.0     | 0.053   | 282|
| isoD7-Aβ42    | male| 56       | 0.0    | 0.7325  | 64         | −3.0     | 0.293   | 278|
| pS8-Aβ42      | female| 67       | 74     |         |            |          |         |    |
| Aβ42          | female| 64       | −4.5*  | 0.0024  | 71         | −4.1     | 0.078   | 301|
| isoD7-Aβ42    | female| 64       | −4.5   | 0.1668  | 74         | 0.0      | 0.554   | 258|
| pS8-Aβ42      | female| 64       | −4.5*  | 0.0022  | 74         | 0.0      | 0.995   | 262|

$M$ (days) - median lifespan; 90% (days) - age of 90% mortality (maximum lifespan); dM (%), d90% (%), − differences between median and maximum (age of 90% mortality) lifespan of control and experimental flies, respectively; n - number of flies; *p < 0.01, FET - Fisher’s exact test (median lifespan comparison), WAT - Boschloo’s (Wang-Allison) test (maximum lifespan comparison)
The same mechanisms underlie the neurotoxic properties of Aβ peptides [4, 37]. The obtained results suggest that the chronic treatment with Aβ in Drosophila leads to prevalence of negative effects over positive ones. The observed negative effect on lifespan is in disagreement with the finding where the extension of Drosophila lifespan was achieved by lowering the production of AMPs in the fat body beginning in the second half of lifespan [21]. This result could be explained by fundamental importance of temporal and tissue-specific control of AMP genes expression in lifespan regulation in contrast to the life-long and global influence of pharmacological treatment with endogenous Aβ. For example, age-associated inflammation in Drosophila fat body may repress AMPs production in the midgut and increase microbial proliferation, contribute to gut hyperplasia,
leakage, and animal death [38]. In our experiments, Aβ peptides were received from food and they could affect AMP genes expression in the intestine with all negative consequences.

At the same time, it was shown that the negative effects of Aβ are not tissue-specific. The expression of the human Aβ42 peptide in adult Drosophila in a tissue- and time-controlled manner revealed that Aβ42 is also toxic in different non-neural cell types, including neurosecretory and epithelial cells [39]. The toxic effect may be associated with the Aβ-induced oxidative stress [14], as was evidenced by an increase in the expression level of Prx5.

It was also previously shown that the toxicity of Aβ overexpression in flies is associated with activation of the insulin/IGF signaling pathway [33]. Pro-longevity gene dFOXO is a component of insulin/IGF signaling pathway and positive regulator of AMPs expression [32]. The observed suppression of the activity of dFOXO by Aβ42 peptides can explain both a decrease of the biosynthesis of AMPs as well as a shortening of lifespan.

We also found differences in the effects of Aβ42 peptides in males and females. It is worth noting that sex differences of lifespan and healthspan effects as well as gene expression level in response to pharmacological treatments or genetic interventions are widespread in Drosophila and other model organisms [35, 36, 40]. We previously showed that activation of expression of AMP genes in response to entomopathogenic fungus demonstrate a sex-specific differences [41]. Both human studies and animal models revealed greater vulnerability to AD in females, while men are more likely to die from virtually all main causes of death [40, 42, 43]. This fact is consistent with our results on the greater susceptibility of females to Aβ42 peptides compared to males. The sex-specific and sex-biased effects of Aβ42 peptides may be related to patterns of gene expression, sex steroid hormones, differences in mitochondrial maintenance failure and other biological mechanisms [40, 43].

It is most difficult to explain the relationship between obtained effects and the isoform of amyloid. IsoD7-Aβ42 is known to be the most aggressive form of Aβ42, enforcing the formation of oligomers and peptide aggregates both in vitro and in mice model [29]. This isoform is much more neurotoxic than the native peptide. Contrary to Aβ42 and isoD7-Aβ42, phosphorylated peptide pS8-Aβ42 reduces plaque deposition in animals, inhibits zinc-dependent aggregation of amyloid, and prevents Na+, K+-ATPase inhibition [44]. At the same time pS8-Aβ42 has a much stronger tendency to spontaneous aggregation than Aβ42 and isoD7-Aβ42.

However, we found the opposite effects in flies. IsoD7-Aβ42 did not induce any effects. It is possible that isoD7-Aβ42 has a stronger antimicrobial property which compensates for its toxicity. The Aβ42 and pS8-Aβ42 affected lifespan despite their toxicity is much less than isoD7-Aβ42. This effects demonstrate that in the case of oral administration the amyloidogenic properties of the peptide do not play a crucial role.

Conclusions
In this study we failed to confirm our suggestion about benefits of exogenous Aβ as a result of its antimicrobial activity. Rather, we revealed the weak negative effect of the oral administration of Aβ42 peptides on Drosophila lifespan. Treatment with Aβ42 and pS8-Aβ42 slightly decreased female’s median lifespan (by 4.5%). However, the effect on lifespan was not established for the more toxic peptide isoform isoD7-Aβ42. We failed to reveal overt effect of Aβ42 peptides on locomotion. The relative levels of AMP gene expression in male flies were largely unaffected by Aβ42 peptide treatment. Aβ42 peptide treatment induced slight decline in AMP genes expression in females regardless of the effects on lifespan. Thus, the oral intake of Aβ42 peptides does not appear to greatly affect fly aging or immunity.

Materials and methods
Drosophila melanogaster lines and maintenance conditions
Wild type Canton-S (#64349, Bloomington Drosophila Stock Center, USA) strain was used in all experiments. Control and experimental animals were maintained on nutrient medium containing 92 g cornmeal, 32.1 g yeast, 5.2 g agar, 136.9 g glucose, and 5 ml of propionic acid

Table 2 Cox proportional hazards analysis. Proportional hazard modeled for Aβ peptide (treatment versus control) and vials (10 vials in each experimental variant) as covariates with partial likelihood estimation

| Variant          | Risk factor | HR   | SE   | P-value |
|------------------|-------------|------|------|---------|
| Aβ42 males       | vial        | 1.048| 0.015| 0.001   |
|                  | Aβ peptide  | 0.924| 0.085| 0.355   |
| Aβ42 females     | vial        | 0.971| 0.029| 0.313   |
|                  | Aβ peptide  | 1.201| 0.083| 0.028   |
| isoD7-Aβ42 males | vial        | 1.054| 0.015| 0.001   |
|                  | Aβ peptide  | 1.008| 0.043| 0.848   |
| isoD7-Aβ42 females| vial     | 0.971| 0.029| 0.313   |
|                  | Aβ peptide  | 0.993| 0.043| 0.861   |
| pS8-Aβ42 males   | vial        | 1.005| 0.004| 0.159   |
|                  | Aβ peptide  | 0.961| 0.029| 0.179   |
| pS8-Aβ42 females | vial        | 0.971| 0.029| 0.313   |
|                  | Aβ peptide  | 1.013| 0.028| 0.643   |

Hazard ratios (HR) indicates fold change of the hazard (risk of death) for variants with higher values of that variable. The risk factor Aβ peptide is encoded by 1 (untreated control) and 2 (treated with Aβ peptide). The vials are numbered from 1 to 10 in each experimental variant as pseudoreplicates. HR greater than one indicates increased risk of death. Significant estimates in bold. SE - standard error
per 1 l. To maintain constant conditions (25 °C, 60% relative humidity, and 12 h/12 h light/dark cycle) the Binder KBF720-ICH (Binder, Germany) climate chamber was used.

**Treatment with beta-amyloid peptides**

Synthetic peptides (purity > 98% checked by RP-HPLC) DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIGLMVGGVIA (Aβ42), DAEFRH [iso-D]SGYEVHHQKLVFFAEDVGSNKGAIGLMVGGVIA (isoD7-Aβ42), and DAEFRH [pS] GYEVHHQKLVFFAEDVGSNKGAIGLMVGGVIA (pS8-Aβ42) were purchased from Biopeptide (San Diego, CA, USA). Peptides were treated with 10% NH₄OH, dried and dissolved in water. Experimental adult flies were treated with synthetic peptides throughout their lifetime. For imago feeding, 30 μl of 20 μM peptide containing water solution was added to cover the media surface in each vial. To each control vial 30 μl of distilled water was added. Vials were dried under the fan for 1–2 h. Flies were flipped onto new media 2 times per week. One time per week the peptides were added to the experimental vials.

**Table 3** Analysis of differences in locomotor activity factored by age and conditions using two-way ANOVA

| Variant   | Source of variation | SS    | DF  | MS      | F         | P-value   | F-crit  |
|-----------|---------------------|-------|-----|---------|-----------|-----------|---------|
| males     |                      |       |     |         |           |           |         |
| pS8-Aβ42  | Condition           | 4231.89 | 1   | 4231.89 | 0.918     | 0.344     | 7.396   |
| Aβ42      | Condition           | 3615.74 | 1   | 3615.74 | 0.623     | 0.435     | 7.396   |
| isoD7-Aβ42| Condition           | 46,787.54 | 1   | 46,787.54 | 4.357     | 0.044     | 7.396   |
| females   |                      |       |     |         |           |           |         |
| pS8-Aβ42  | Condition           | 148.05  | 1   | 148.05  | 0.32      | 0.575     | 7.396   |
| Aβ42      | Condition           | 3605.33 | 1   | 3605.33 | 6.954     | 0.012     | 7.396   |
| isoD7-Aβ42| Condition           | 3918.66 | 1   | 3918.66 | 4.696     | 0.037     | 7.396   |

SS Sum-of-squares, DF degrees of freedom, MS mean squares. Results of F-tests: F-value (F), P-value, F-critical value (F-crit). Significant estimates in bold.
The primer design was performed using QuantPrime [45]. The reaction was carried out on the CFX96 Real-Time PCR Detection System (Bio-Rad, USA) using the following parameters: one cycle of 95 °C for 30 s; 40 cycles of 95 °C for 10 s and 60 °C for 30 s. Expression levels of target genes was calculated relative to the expression of reference genes: β-Tubulin56D (βTub56D), eukaryotic Elongation Factor 1α1 (eEF1α1), and Ribosomal protein L32 (Rpl32) using the Bio-Rad CFX Manager 3.1 (Bio-Rad, USA). Experiments were made in 3 independent biological replicates, with 3 technical replicates in each.

The primer design was performed using QuantPrime [45]. The reaction was carried out on the CFX96 Real-Time PCR Detection System (Bio-Rad, USA) using the following parameters: one cycle of 95 °C for 30 s; 40 cycles of 95 °C for 10 s and 60 °C for 30 s. Expression levels of target genes was calculated relative to the expression of reference genes: β-Tubulin56D (βTub56D), eukaryotic Elongation Factor 1α1 (eEF1α1), and Ribosomal protein L32 (Rpl32) using the Bio-Rad CFX Manager 3.1 (Bio-Rad, USA). Experiments were made in 3 independent biological replicates, with 3 technical replicates in each.

The primer design was performed using QuantPrime [45]. The reaction was carried out on the CFX96 Real-Time PCR Detection System (Bio-Rad, USA) using the following parameters: one cycle of 95 °C for 30 s; 40 cycles of 95 °C for 10 s and 60 °C for 30 s. Expression levels of target genes was calculated relative to the expression of reference genes: β-Tubulin56D (βTub56D), eukaryotic Elongation Factor 1α1 (eEF1α1), and Ribosomal protein L32 (Rpl32) using the Bio-Rad CFX Manager 3.1 (Bio-Rad, USA). Experiments were made in 3 independent biological replicates, with 3 technical replicates in each.

Lifespan analysis

Newly eclosed flies were collected within 24 h and sorted by sex using light carbon dioxide anesthesia, and at density of 30 flies were housed in narrow vials (Genesee Scientific, USA). The number of dead flies was counted every day. For each experiment 2 replicates of 5 vials (150 flies) were analyzed. The median lifespan, maximum lifespan (age of 90% mortality), and the mortality rate doubling time (MRDT) were calculated.

Locomotor activity analysis

The rate of spontaneous locomotor activity was measured using the LAM25 Locomotor Activity Monitor (TriKinetics Inc., USA). The data from 30 flies in 4 vials as replicates were collected during 24 h and represented as average daily locomotor activity per fly. Measurements were carried out every week, from the age of 3 to 9 weeks.

Real-time quantitative reverse transcription PCR

Freshly emerged imagoes were collected within 24 h and treated with amyloid peptides for 10 days. The gene expression analyses were carried out using whole bodies of 20 males or 10 females per variant of experiment. Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) were used to measure the expression levels of genes related to immune response (Cecropin A1 (CecA1), Defensin (Def), Drosocin (Dro), Drosomycin (Drs), Metchnikowin (Mtk), and Peroxiredoxin 5 (Prx5)) and to insulin/IGF signaling pathway (Drosophila homolog of forkhead box O (FOXO) transcription factors (dFOXO)).

RNA was isolated by Aurum Total RNA mini kit (BioRad, USA). To determine total RNA concentration was used Quant-iT RNA Assay Kit (Invitrogen, USA). Reverse transcription was performed using the iScript cDNA Synthesis Kit (Bio-Rad, USA). The mix for RT-PCR was prepared by iTaq Universal SYBR Green Supermix (Bio-Rad, USA) with primers listed in Table 4.

Table 4 List of primers used for real-time qRT-PCR analysis of gene expression

| Gene            | Forward                 | Reverse                 |
|-----------------|-------------------------|-------------------------|
| βTub56D         | 5'-ggcccaactgaagctgatct-3' | 5'-aagccgggcataagaagtg-3' |
| eEF1α1          | 5'-aggccaaagtcgtctggc-3'  | 5'-gtctgtactactctgttg-3'  |
| RpL32           | 5'-acagggcccaatctgtaag-3' | 5'-ttgtgtgcatacctggcag-3' |
| Cecropin A1     | 5'-tcgtctacactctgaactatc-3' | 5'-tgcctaaatctgtaagccaaag-3' |
| Defensin        | 5'-gttctgtcgtctgtcctgc-3'  | 5'-atccacatcgcactttagc-3'  |
| Drosocin        | 5'-tcagcgtcctagctgccacca-3' | 5'-atcagggacctttgtacttccc-3' |
| Drosomycin      | 5'-aagctatggcctctttcgcc-3' | 5'-acagggacctttgtacttccc-3' |
| Metchnikowin    | 5'-tcgcccccaatcctcttacaccc-3' | 5'-acgacatcgcagttgaatctcc-3' |
| Peroxiredoxin S | 5'-ccgatgagttgctgaagagta-3' | 5'-ttcgctttttcaccacacc-3' |
| dFOXO           | 5'-tagcagtgccgagattgaagaac-3' | 5'-acccctataaagcgcgtgctgag-3' |
was done with STATISTICA 6.1 (StatSoft, USA). Real-time qRT-PCR data were analyzed using the Bio-Rad CFX Manager 3.1 (Bio-Rad, USA).

Abbreviations
Aβ: Amyloid-β peptide; Aβ42: Beta-amyloid peptide 42; AD: Alzheimer's disease; AMP: Antimicrobial peptide; ANOVA: Analysis of variance; IMD: Immune deficiency; isoD7-Aβ42: Aβ42 peptide with isomerized aspartic acid at the 7th residue; pS6-Aβ42: Aβ42 peptide with phosphorylated serine at the 8th residue, qRT-PCR: quantitative reverse transcription polymerase chain reaction; RP-HPLC: Reversed phase high-performance liquid chromatography.

Acknowledgments
We thank the IB FRC Komi SC UB RAS for the collection of Drosophila lines, and the EMB RAS for scientific advice, beta-amyloid peptide samples, and for assistance in data analysis.

About this supplement
This article has been published as part of BMC Genetics Volume 21 Supplement 1, 2020: Selected Topics in Systems Biology and Bioinformatics - 2019: genetics. The full contents of the supplement are available online at https://bmcgenet.biomedcentral.com/articles/supplements/volume-21-supplement-1.

Authors’ contributions
MVS, NVZ, LAK, AAMosk wrote the manuscript text. NVZ, LAK, NRM, OK carried out the experiments. VAM, AAMak, AAMosk supervised the text of the manuscript. All authors read and approved the final manuscript.

Funding
The study and publication costs have been funded by the Russian Science Foundation (Grant #19–74-30007). The funding body had no role in study design, data collection, analysis and interpretation, or preparation of the manuscript.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
All authors declare no competing interests.

Published: 22 October 2020

References
1. Murphy MP, LeVine H Srd. Alzheimer's disease and the β-amyloid peptide. J Alzheimers Dis. 2010;19(1):1–23.
2. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4): 388–405.
3. Ewald CY, Li C. Caenorhabditis elegans as a model organism to study APP function. Exp Brain Res. 2012;217(3–4):397–411.
4. Pozueta J, Lefort R, Shelanski ML. Synaptic changes in Alzheimer’s disease and its models. Neuroscience. 2013;251:151–65.
5. Li JJ, Dolio G, Wang R, Liao FF. Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal microRNA expression. PLoS One. 2014;9(3):e90770.
6. Brothers HM, Gosztyla ML, Robinson SR. The physiological roles of amyloid-β peptide hint at new ways to treat Alzheimer’s disease. Front Aging Neurosci. 2018;10:1118.
7. Gosztyla ML, Brothers HM, Robinson SR. Alzheimer’s amyloid-beta is an antimicrobial peptide: a review of the evidence. J Alzheimers Dis. 2018;62(4): 1495–506.
8. Kumar DK, Choi SH, Wachosky KJ, Eimer WA, Tucker S, Ghofrani J, et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci Transl Med. 2016;8(340):340ra–372.
9. Soscia SJ, Kibby JE, Wachosky KJ, Tucker SM, Ingelsson M, Hyman B, et al. The Alzheimer’s disease-associated amyloid β-protein is an antimicrobial peptide. PLoS One. 2010;5(5):e9505.
10. Finelli A, Kelkar A, Song HY, Yang H, Konsolaki M. A model for studying Alzheimer’s Aβ42-induced toxicity in Drosophila melanogaster. Mol Cell Neurosci. 2004;26(3):365–75.
11. Prussing K, Voigt A, Schulz JB. Drosophila melanogaster as a model organism for Alzheimer’s disease. Mol Neurodegener. 2013;8:35.
12. Bilen J, Bonini NM. Drosophila as a model for human neurodegenerative disease. Annu Rev Genet. 2005;39:153–71.
13. Greeve I, Kretzschmar D, Tsachea JA, Beyn A, Brillenberg C, Schweizer M, et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci. 2004;24(16):3899–906.
14. Rival T, Page RM, Chandraratna DS, Sendall TJ, Ryder E, Liu B, et al. Fenton chemistry and oxidative stress mediate the toxicity of the β-amyloid peptide in a Drosophila model of Alzheimer’s disease. Eur J Neurosci. 2009; 29(7):1335–47.
15. Liu H, Han M, Li Q, Zhang X, Wang WA, Huang FD. Automated rapid iterative negative geotaxis assay and its use in a genetic screen for modifiers of Aβ42-induced locomotor decline in Drosophila. Neurosci Bull. 2015;31(5):541–9.
16. Iijima K, Liu HP, Chiang AS, Heam SA, Konsolaki M, Zhong Y. Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: a potential model for Alzheimer’s disease. Proc Natl Acad Sci U S A. 2004;101(7):6623–8.
17. Keebaugh ES, Yamada R, Obadia B, Ludington WB, Ja WW. Microbial quantity impacts Drosophila nutrition, development, and lifespan. iScience. 2018;4:247–59.
18. Zhao HW, Zhou D, Haddad GG. Antimicrobial peptides increase tolerance to oxidant stress in Drosophila melanogaster. J Biol Chem. 2011;286(6):6211–8.
19. Zoch G, Zinke I, Mori T, Carrera P, Schoer J, Takeyama H, et al. Antimicrobial peptides extend lifespan in Drosophila. PLoS One. 2017;12(5):e0176689.
20. Shaposhnikov M, Larkin D, Plyusnina E, Shilova L, Danilov A, Popov S, et al. The effects of pectins on life span and stress resistance in Drosophila melanogaster. Biogerontology. 2014;15(2):113–27.
21. Badinloo M, Nguyen E, Suh W, Alzahrani F, Castellanos J, Klichko VI, et al. Overexpression of antimicrobial peptides contributes to aging through cytoptotic effects in Drosophila tissues. Arch Insect Biochem Physiol. 2018; 98(4):e21464.
22. Fletcher SD, Macdonald SJ, Marguerie R, Certa U, Stearns SC, Goldstein DB, et al. Genome-wide transcript profiles in aging and calorically restricted Drosophila melanogaster. Curr Biol. 2002;12(9):712–23.
23. Landis GN, Abdueva D, Skvortsov D, Yang J, Rabin BE, Carrick J, et al. Similar gene expression patterns characterize aging and oxidative stress in Drosophila melanogaster. Proc Natl Acad Sci U S A. 2004;101(20): 7663–8.
24. Moskalev A, Shaposhnikov M. Pharmacological inhibition of NF-κB prolongs lifespan of Drosophila melanogaster. Aging (Albany NY). 2011;3(4):391–4.
25. Libert S, Chao Y, Chu X, Fletcher SD. Trade-offs between longevity and pathogen resistance in Drosophila melanogaster are mediated by NFκB signaling. Aging Cell. 2006;5(6):533–43.
26. Cao Y, Chitarbanova S, Petersen AJ, Ganetzky B. Dn1 mutations cause neurodegeneration in Drosophila by activating the innate immune response in the brain. Proc Natl Acad Sci U S A. 2013;110(19):E1752–60.
27. Kounatidis I, Chitarbanova S, Cao Y, Hayme M, Janyan D, Ganetzky B, et al. NF-κB immunity in the brain determines fly lifespan in healthy aging and age-related neurodegeneration. Cell Rep. 2017;19(4):836–48.
28. Sargaeva NP, Lin C, O’Connor PB. Identification of aspartic and isoaspartic acid residues in amyloid β peptides, including Aβ 1–42, using electron-ion reactions. Anal Chem. 2009;81(23):9778–86.
29. Kozin SA, Mitkevich VA, Makarov AA. Amyloid-β containing isoaspartate 7 as potential biomarker and drug target in Alzheimer’s disease. Mendeleev Communications. 2016;26(4):269–75.
30. Kumar S, Rezaei-Ghaileh N, Terwel D, Thal DR, Richard M, Hoch M, et al. Extracellular phosphorylation of the amyloid-β peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer’s disease. EMBO J. 2011;30(11):2255–65.
31. Radyuk SN, Michalak K, Klichko VI, Benes J, Orr WC. Peroxiredoxin 5 modulates immune response in Drosophila. Biochim Biophys Acta. 2010;1800(11):1153–63.
32. Becker T, Loch G, Moyer M, Zinke I, Aschenbrenner AC, Carrera P, et al. FOXO-dependent regulation of innate immune homeostasis. Nature. 2010;463(7279):369–73.
33. Huang Y, Wan Z, Wang Z, Zhou B. Insulin signalling in Drosophila melanogaster mediates AB toxicity. Commun Biol. 2019;2(1):13.
34. Ziehm M, Piper MD, Thornton JM. Analysing variation in Drosophila aging across independent experimental studies: a meta-analysis of survival data. Aging Cell. 2013;12(5):917–22.
35. Moskalev A, Shaposhnikov M, Proshkina E, Belyi A, Fedintsev A, Zhikrivetskaya S, et al. The influence of pro-longevity gene Gcl overexpression on the age-dependent changes in Drosophila transcriptome and biological functions. BMC Genomics. 2016;17(5):273–89.
36. Shaposhnikov MV, Zemskaya NV, Koval LA, Schegoleva EV, Zhavoronkov A, Moskalev AA. Effects of N-acetyl-L-cysteine on lifespan, locomotor activity and stress-resistance of 3 Drosophila species with different lifespans. Aging (Albany NY). 2018;10(9):2428–58.
37. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101–12.
38. Chen H, Zheng X, Zheng Y. Age-associated loss of Lamin-B leads to systemic inflammation and gut hyperplasia. Cell. 2014;159(4):829–43.
39. Améz M, Casas-Tintó S, Malmendal A, Fernus A. Amyloid β42 peptide is toxic to non-neural cells in Drosophila yielding a characteristic metabolite profile and the effect can be suppressed by PI3K. Biol Open. 2017;6(1):1664–71.
40. Austad SN, Barke A. Sex differences in longevity and in responses to anti-aging interventions: a mini-review. Gerontology. 2015;62(1):40–6.
41. Moskalev A, Zhikrivetskaya S, Krasnov G, Shaposhnikov M, Proshkina E, Borisoglebsky D, et al. A comparison of the transcriptome of Drosophila melanogaster in response to entomopathogenic fungus, ionizing radiation, starvation and cold shock. BMC Genomics. 2015;16(Suppl 1):S8.
42. Medeiros AM, Silva RH. Sex differences in Alzheimer’s disease: where do we stand? J Alzheimer’s Dis. 2019;67(1):35–60.
43. Tower J. Sex-specific gene expression and life span regulation. Trends Endocrinol Metab. 2017;28(10):735–47.
44. Arvidsson S, Kwasniewski M, Riano-Pachon DM, Mueller-Roeber B. QuantPrime – a flexible tool for reliable high-throughput primer design for quantitative PCR. BMC Bioinformatics. 2008;9(1):465.
45. Mehta CR, Patel NR, Tsatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics. 1984;40(3):819–25.
46. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163–70.
47. Fleming TR, O’Fallon JR, O’Brien PC, Harrington DP. Modified Kolmogorov-Smirnov test procedures with application to arbitrarily right-censored data. Biometrics. 1980;36(4):607–25.
48. Han SK, Lee D, Lee H, Kim D, Son HG, Yang JS, et al. OASIS 2: online application for survival analysis 2 with features for the analysis of maximal lifespan and healthspan in aging research. Oncotarget. 2016;7(35):56147–52.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions